Competitive AdvantagePedmark has IP protection until 2039 and orphan drug status until 2029, providing a competitive advantage in the market.
Market ExpansionFennec remains poised to reap benefits from market expansion to the adolescent and young adult (AYA) community with payor reimbursement, along with accelerating product adoption at key academic centers.
Product AdoptionPedmark has been included into National Comprehensive Cancer Network (NCCN) guidelines for the AYA oncology patient population, significantly increasing average revenue per patient.